{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:33:30Z","timestamp":1792474410500,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Arab Journal of Gastroenterology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ajg.2025.11.004","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:32:04Z","timestamp":1769517124000},"page":"113-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of allopurinol in metabolic dysfunction-associated steatotic liver disease: A randomized clinical trial"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6877-3366","authenticated-orcid":false,"given":"Elnaz","family":"Khani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manouchehr","family":"Khoshbaten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Asghari","family":"Jafarabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4808-6179","authenticated-orcid":false,"given":"Haleh","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrnaz","family":"Rahmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elnaz","family":"Shaseb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajg.2025.11.004_b0005","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ajg.2025.11.004_b0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.ajg.2025.11.004_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11133649","article-title":"The role of insulin resistance in fueling NAFLD pathogenesis: from molecular mechanisms to clinical implications","volume":"11","author":"Palma","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajg.2025.11.004_b0020","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3748\/wjg.v26.i15.1683","article-title":"Determining the role for uric acid in non-alcoholic steatohepatitis development and the utility of urate metabolites in diagnosis: an opinion review","volume":"26","author":"Brennan","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ajg.2025.11.004_b0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011128","article-title":"The interplay between insulin resistance, inflammation, oxidative stress, base excision repair and metabolic syndrome in nonalcoholic fatty liver disease","volume":"22","author":"Ziolkowska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajg.2025.11.004_b0030","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.clinbiochem.2007.02.006","article-title":"Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis","volume":"40","author":"Baskol","year":"2007","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ajg.2025.11.004_b0035","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ajg.2025.11.004_b0040","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajg.2025.11.004_b0045","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajg.2025.11.004_b0050","unstructured":"Administration. USFaD. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. 2024 [cited March 14, 2024]; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease."},{"key":"10.1016\/j.ajg.2025.11.004_b0055","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.semarthrit.2019.11.009","article-title":"Beyond urate lowering: Analgesic and anti-inflammatory properties of allopurinol","volume":"50","author":"Schlesinger","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ajg.2025.11.004_b0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2174\/1570161115666170621082237","article-title":"Can serum uric acid lowering therapy contribute to the prevention or treatment of nonalcoholic fatty liver disease?","volume":"16","author":"Paschos","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.ajg.2025.11.004_b0065","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2147\/CLEP.S403314","article-title":"Association between serum uric acid and non-alcoholic fatty liver disease: an updated systematic review and meta-analysis","volume":"15","author":"Sun","year":"2023","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ajg.2025.11.004_b0070","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/MEG.0000000000000931","article-title":"Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"29","author":"Jaruvongvanich","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ajg.2025.11.004_b0075","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2036.2011.04788.x","article-title":"Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease","volume":"34","author":"Petta","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ajg.2025.11.004_b0080","doi-asserted-by":"crossref","first-page":"40732","DOI":"10.1074\/jbc.M112.399899","article-title":"Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver","volume":"287","author":"Lanaspa","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajg.2025.11.004_b0085","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbrc.2014.04.080","article-title":"High uric acid directly inhibits insulin signalling and induces insulin resistance","volume":"447","author":"Zhu","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ajg.2025.11.004_b0090","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.jhep.2015.01.019","article-title":"Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: one stone hits two birds","volume":"62","author":"Xu","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajg.2025.11.004_b0095","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1038\/s41598-021-88872-7","article-title":"Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway","volume":"11","author":"Cho","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajg.2025.11.004_b0100","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41598-020-57784-3","article-title":"Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice","volume":"10","author":"Nishikawa","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajg.2025.11.004_b0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5114\/ceh.2019.83159","article-title":"Allopurinol potentiates the hepatoprotective effect of metformin and vitamin E in fructose-induced fatty liver in rats","volume":"5","author":"Khalaf","year":"2019","journal-title":"Clin Exp Hepatol"},{"key":"10.1016\/j.ajg.2025.11.004_b0110","article-title":"Magnetic resonance imaging-proton density fat fraction vs. transient elastography-controlled attenuation parameter in diagnosing non-alcoholic fatty liver disease in children and adolescents: a meta-analysis of diagnostic accuracy","volume":"9","author":"Jia","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.ajg.2025.11.004_b0115","first-page":"218","article-title":"Correlation between serum uric acid and non-alcoholic fatty liver disease: a cross-sectional study","volume":"4","author":"Khani","year":"2022","journal-title":"J Pharm Care"}],"container-title":["Arab Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197925001728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197925001728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T04:31:23Z","timestamp":1771389083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1687197925001728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1687197925001728"],"URL":"https:\/\/doi.org\/10.1016\/j.ajg.2025.11.004","relation":{},"ISSN":["1687-1979"],"issn-type":[{"value":"1687-1979","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of allopurinol in metabolic dysfunction-associated steatotic liver disease: A randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Arab Journal of Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajg.2025.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}